GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Iconovo AB (OSTO:ICO) » Definitions » DeferredTaxAndRevenue

Iconovo AB (OSTO:ICO) DeferredTaxAndRevenue : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Iconovo AB DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Iconovo AB's current deferred tax and revenue for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Iconovo AB DeferredTaxAndRevenue Historical Data

The historical data trend for Iconovo AB's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iconovo AB DeferredTaxAndRevenue Chart

Iconovo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only - - - - -

Iconovo AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Iconovo AB DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Iconovo AB's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Iconovo AB Business Description

Traded in Other Exchanges
N/A
Address
Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.

Iconovo AB Headlines

No Headlines